James Huang

James Huang is a member of the Board of Directors at Kainova Therapeutics. He is Founding Managing Partner of Panacea Healthcare Venture Capital and Managing Partner of Kleiner Perkins China. He has more than thirty years of experience in the life sciences and investment sector, spanning venture capital, company creation, and senior leadership roles.

Mr. Huang was previously a Managing Partner at Vivo Ventures. Before joining Vivo in 2007, he served as President of Anesiva, a biopharmaceutical company focused on pain-management treatments. Earlier in his career, he held senior positions in business development, marketing, and R&D at several global healthcare companies, including Tularik Inc. (acquired by Amgen), GlaxoSmithKline LLC, Bristol-Meyers Squibb, and ALZA Corp. (acquired by Johnson & Johnson).

Mr. Huang holds an M.B.A. from the Stanford Graduate School of Business and a B.S. degree in chemical engineering from the University of California, Berkeley.